The Wall Street Journal and other news outlets are reporting that on June 19, Zicam manufacturer Matrixx Inc. received an informal inquiry from the Securities and Exchange Commission regarding its line of recently recalled Zicam cold remedy products.  As we reported previously, Matrixx recalled Zicam nasal spray and swabs after the Food and Drug Administration (“FDA”) received over 30 reports that the products could lead to anosmia, or loss of smell, and that these side effects could be permanent. 

According to the Wall Street Journal, the SEC is asking for documents related to the FDA warning letter sent on June 16.  This letter contained the FDA’s concerns that Zicam could lead to anosmia.  The product was recalled the next day.  A Matrixx spokesperson says that the company will fully comply with the SEC request.

Zicam lawyers are currently investigating potential Zicam lawsuits and some Zicam lawsuits have already been filed.  Bernstein Liebhard lawyers are available for a free legal consultation about potential Zicam claims.

Tags: Pharmaceutial Litigation, Zicam

This entry was posted on Wednesday, June 24th, 2009 at 3:30 pm and is filed under Zicam. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.